Hiroaki Akamatsu

9.1k total citations · 1 hit paper
144 papers, 5.1k citations indexed

About

Hiroaki Akamatsu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Hiroaki Akamatsu has authored 144 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Oncology, 100 papers in Pulmonary and Respiratory Medicine and 25 papers in Epidemiology. Recurrent topics in Hiroaki Akamatsu's work include Lung Cancer Treatments and Mutations (82 papers), Lung Cancer Research Studies (52 papers) and Lung Cancer Diagnosis and Treatment (28 papers). Hiroaki Akamatsu is often cited by papers focused on Lung Cancer Treatments and Mutations (82 papers), Lung Cancer Research Studies (52 papers) and Lung Cancer Diagnosis and Treatment (28 papers). Hiroaki Akamatsu collaborates with scholars based in Japan, United States and South Korea. Hiroaki Akamatsu's co-authors include Yi‐Long Wu, Suresh S. Ramalingam, Myung‐Ju Ahn, Frances A. Shepherd, Helen Mann, Tony Mok, Martin Sebastian, Yong He, Willemijn S.M.E. Theelen and Vassiliki A. Papadimitrakopoulou and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Hiroaki Akamatsu

135 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

2016 2.4k citations Yi‐Long Wu, Myung‐Ju Ahn et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hiroaki Akamatsu Japan	28	3.8k	3.5k	1.2k	1.1k	309	144	5.1k
Manuel Cobo Spain	30	3.4k 0.9×	3.6k 1.0×	1.3k 1.1×	1.1k 1.0×	166 0.5×	219	5.3k
Hidetoshi Hayashi Japan	36	2.8k 0.7×	3.7k 1.1×	1.4k 1.2×	705 0.6×	270 0.9×	248	5.2k
Shinji Atagi Japan	36	3.3k 0.9×	3.2k 0.9×	819 0.7×	430 0.4×	491 1.6×	182	4.5k
Roberto Iacovelli Italy	34	2.6k 0.7×	2.1k 0.6×	1.5k 1.3×	1.2k 1.1×	248 0.8×	224	4.6k
Sarayut Lucien Geater Thailand	21	5.3k 1.4×	4.6k 1.3×	1.6k 1.3×	1.1k 1.0×	120 0.4×	91	6.2k
Shunichi Sugawara Japan	36	3.5k 0.9×	4.2k 1.2×	1.1k 0.9×	548 0.5×	507 1.6×	209	5.4k
Radj Gervais France	24	4.0k 1.1×	3.7k 1.1×	1.1k 0.9×	617 0.6×	246 0.8×	83	5.2k
N. Moore Switzerland	16	2.6k 0.7×	2.0k 0.6×	1.7k 1.4×	1.2k 1.1×	125 0.4×	27	4.0k
Lorinda Simms United States	18	3.6k 1.0×	3.5k 1.0×	997 0.8×	848 0.8×	165 0.5×	38	5.1k
Mircea Dediu Romania	19	5.1k 1.4×	4.8k 1.4×	1.6k 1.3×	894 0.8×	267 0.9×	55	6.6k

Countries citing papers authored by Hiroaki Akamatsu

Since Specialization

Citations

This map shows the geographic impact of Hiroaki Akamatsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroaki Akamatsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroaki Akamatsu more than expected).

Fields of papers citing papers by Hiroaki Akamatsu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroaki Akamatsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroaki Akamatsu. The network helps show where Hiroaki Akamatsu may publish in the future.

Co-authorship network of co-authors of Hiroaki Akamatsu

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroaki Akamatsu. A scholar is included among the top collaborators of Hiroaki Akamatsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroaki Akamatsu. Hiroaki Akamatsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hummel, Horst-Dieter, Myung‐Ju Ahn, Fiona Blackhall, et al.. (2025). Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 Trial. Advances in Therapy. 42(4). 1950–1964. 1 indexed citations

Fujimoto, Daichi, Ryota Shibaki, Keiichi Kimura, et al.. (2025). Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning. Lung Cancer. 199. 108079–108079. 1 indexed citations

Lü, Shun, Jonathan W. Goldman, Junko Tanizaki, et al.. (2024). A phase 3 global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met 0verexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01).. Journal of Clinical Oncology. 42(16_suppl). TPS8656–TPS8656. 4 indexed citations

Leighl, Natasha B., Hiroaki Akamatsu, Ying Cheng, et al.. (2024). Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.. Journal of Clinical Oncology. 42(17_suppl). LBA8505–LBA8505. 12 indexed citations

Hayashi, Hidetoshi, Makoto Nishio, Hiroaki Akamatsu, et al.. (2024). Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer. Cancer Research Communications. 4(11). 2858–2867. 2 indexed citations

Nosaki, Kaname, Yoshitaka Zenke, T. Sasaki, et al.. (2024). JCOG2002: A randomized phase III study of thoracic radiotherapy for extensive stage small cell lung cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS8132–TPS8132. 2 indexed citations

Barlési, Fabrice, Enriqueta Felip, Sanjay Popat, et al.. (2024). Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202).. Journal of Clinical Oncology. 42(16_suppl). TPS8653–TPS8653. 4 indexed citations

Ozawa, Yuichi, Yasuhiro Koh, Ryota Shibaki, et al.. (2024). Uncovering the role of tumor cGAS expression in predicting response to PD-1/L1 inhibitors in non-small cell lung cancer. Cancer Immunology Immunotherapy. 74(1). 7–7. 4 indexed citations

Akamatsu, Hiroaki, et al.. (2024). Can FDG‐PET after neoadjuvant chemotherapy plus nivolumab predict residual disease in non‐small cell lung cancer?. SHILAP Revista de lepidopterología. 12(8). e70007–e70007. 1 indexed citations

10.

Shimokawa, Tsuneo, Hiroaki Okamoto, Ryunosuke Machida, et al.. (2023). Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial. Lung Cancer. 181. 107195–107195. 4 indexed citations

11.

Akamatsu, Hiroaki, Shunsuke Teraoka, Masanori Tanaka, et al.. (2023). A Phase II Study of High-Flow Nasal Cannula for Relieving Dyspnea in Advanced Cancer Patients. Journal of Pain and Symptom Management. 67(3). 204–211.e1. 3 indexed citations

12.

Akamatsu, Hiroaki, Shunsuke Teraoka, Shinkichi Takamori, et al.. (2022). Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L). Clinical Cancer Research. 28(15). 3207–3213. 22 indexed citations

13.

Servetto, Alberto, Rahul K. Kollipara, Luigi Formisano, et al.. (2021). Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER+ Breast Cancer. Clinical Cancer Research. 27(15). 4379–4396. 44 indexed citations

14.

Hanker, Ariella B., Benjamin P. Brown, Jens Meiler, et al.. (2021). Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity. Cancer Cell. 39(8). 1099–1114.e8. 53 indexed citations

15.

Inaba, Hidefumi, Hiroyuki Ariyasu, Hiroshi Iwakura, et al.. (2020). Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune‐checkpoint inhibitors. Cancer Science. 111(5). 1468–1477. 109 indexed citations

16.

Murakami, Eriko, et al.. (2019). Furosemide versus mannitol in Japanese patients with thoracic malignancy who received cisplatin-based chemotherapy using short hydration: study protocol for a randomised controlled trial. BMJ Open. 9(12). e029057–e029057. 2 indexed citations

17.

Akamatsu, Hiroaki, Shunsuke Teraoka, Yasuhiro Koh, et al.. (2018). A Phase II Study of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer who Responded to Prior PD-1/L1 Inhibitors: West Japan Oncology Group 9616L (WJOG9616L). Clinical Lung Cancer. 20(2). 139–141. 5 indexed citations

18.

Akamatsu, Hiroaki, Hideyuki Harada, Shoji Tokunaga, et al.. (2018). A Phase II Study of Gefitinib With Concurrent Thoracic Radiotherapy in Patients With Unresectable, Stage III Non–small-cell Lung Cancer Harboring EGFR Mutations (WJOG6911L). Clinical Lung Cancer. 20(1). e25–e27. 18 indexed citations

19.

Akamatsu, Hiroaki, Yasuhiro Koh, Yuichi Ozawa, et al.. (2018). Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib Study. Clinical Lung Cancer. 19(6). e871–e874. 12 indexed citations

20.

Akamatsu, Hiroaki, Asuka Tsuya, Kyoichi Kaira, et al.. (2010). Intestinal metastasis from non-small-cell lung cancer initially detected by 18F-fluorodeoxyglucose positron emission tomography. Japanese Journal of Radiology. 28(9). 684–687. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact